Waterloo Technology profiles Compounds in blood of COVID-19 Sufferers Kumar Jeetendra | July 29, 2020 A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses such as cancer and COVID-19, is expanding operations with the support of a 5-million USD investment. Bin Ma, a University of Waterloo computer engineering professor who co-founded Rapid Novor at 2015, says that the company’s technologies is the most …
Immunomodulatory drugs improve the achievement pace of cancer therapy Kumar Jeetendra | February 15, 2021 Immunomodulatory drugs, for example, Contergan derivatives lenalidomide and pomalidomide, have significantly improved the treatment of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action within this class of drugs. At exactly the exact same time, they identified new revolutionary targeted cancer therapies. …
Alembic Gets USFDA Nod for Doxorubicin Liposome Injection Kumar Jeetendra | June 30, 2025 30th June, 2025 Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. The approved ANDA is therapeutically equivalent …
